Patients who are at high-risk for adverse events from the carotid endarterectomy procedure were included in this study. This would then include symptomatic patients with ≥ 50% or asymptomatic patients with ≥ 80% stenosis in their carotid artery. The primary endpoints for the study are major adverse events which include death, any myocardial infarction or stroke up to 30 days after the stenting procedure. Secondary outcomes such as the effect of symptom status, age, gender and high risk entry criteria were also analyzed.
Dr. Metzger is compensated for his services as a consultant to Cordis Corporation.
About Cordis Corporation
Cordis Corporation, part of the Johnson & Johnson family of companies, is a worldwide leader in the development and manufacture of interventional vascular technology. Through the company's innovation, research and development, Cordis partners with interventional cardiologists worldwide to treat millions of patients who suffer from vascular disease. More information about Cordis Corporation can be found at